Louisiana State University Health Sciences Center Shreveport
lsuhs.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
44
Active
7
Phase 3
2
Total enrollment
3,344
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Lumateperone 42 mg | — | — | — | — | — | 1 | |
| Risperidone 2 mg | — | — | — | — | — | 1 |
Next readouts
- 2026-12
Top conditions
- Mild Cognitive Impairment3
- Movement, Abnormal3
- Lower Extremity Problem3
- Schizophrenia3
- Osteoarthritis, Knee2
- Healthy2
- Breast Cancer2
- Schizoaffective Disorder2
Frequently asked questions about Louisiana State University Health Sciences Center Shreveport
- How many clinical trials does Louisiana State University Health Sciences Center Shreveport have on ClinicalTrials.gov?
- Louisiana State University Health Sciences Center Shreveport is listed as the lead sponsor on 44 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Louisiana State University Health Sciences Center Shreveport's trials are in Phase 3?
- 2 of Louisiana State University Health Sciences Center Shreveport's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Louisiana State University Health Sciences Center Shreveport focus on?
- Louisiana State University Health Sciences Center Shreveport's most-studied conditions on ClinicalTrials.gov are Mild Cognitive Impairment, Movement, Abnormal, Lower Extremity Problem, Schizophrenia, Osteoarthritis, Knee.
- When are Louisiana State University Health Sciences Center Shreveport's next clinical trial readouts?
- Louisiana State University Health Sciences Center Shreveport has 1 upcoming primary-completion readout tracked here; the soonest is “Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.”, expected around 2026-12.